Mao Yu, Liu Yang, Zhai Mengen, Yang Jian
Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 710032 Xi'an, Shaanxi, China.
Rev Cardiovasc Med. 2023 Feb 14;24(2):61. doi: 10.31083/j.rcm2402061. eCollection 2023 Feb.
Mitral valve (MV) disease is one of the most common valvular diseases that endangers health status. A variety of catheter-based interventions have been developed to treat MV disease. The special anatomical structures of the MV complex increase the difficulty of interventional surgery, and the incidence of perioperative complications remains high. With the continuous development of cardiovascular 3-dimensional (3D) printing technology and of multidisciplinary cooperation, 3D printing for transcatheter mitral valve interventions (TMVI) has become a revolutionary technology to promote innovation and improve the success rate. Patient-specific 3D printed models have been used in measuring sizes and predicting perioperative complications before TMVI. By simulating a bench test and using multi-material printing, surgeons may learn how the device interacts with the specific anatomical structures of the MV. This review summarizes relevant cutting-edge publications in this field and illustrates the application of 3D printing in TMVI with examples. In addition, we discuss the limitations and future directions of 3D printing in TMVI.
ClinicalTrials.gov Protocol Registration System (NCT02917980).
二尖瓣疾病是最常见的危及健康状况的瓣膜疾病之一。已经开发出多种基于导管的干预措施来治疗二尖瓣疾病。二尖瓣复合体的特殊解剖结构增加了介入手术的难度，围手术期并发症的发生率仍然很高。随着心血管三维（3D）打印技术和多学科合作的不断发展，用于经导管二尖瓣介入治疗（TMVI）的3D打印已成为一项促进创新并提高成功率的革命性技术。患者特异性3D打印模型已用于在TMVI之前测量尺寸和预测围手术期并发症。通过模拟台架试验并使用多材料打印，外科医生可以了解该装置如何与二尖瓣的特定解剖结构相互作用。本综述总结了该领域的相关前沿出版物，并举例说明了3D打印在TMVI中的应用。此外，我们讨论了3D打印在TMVI中的局限性和未来方向。
ClinicalTrials.gov协议注册系统（NCT02917980）。
